Amgen Targets Mild Pediatric Psoriasis with PDE4 Inhibitor in New Phase 3 Trial

Amgen's Latest Trial Registration

• Amgen has initiated a late-stage trial named "A Study of Apremilast for Children with Mild to Moderate Plaque Psoriasis." This research seeks to assess the safety and tolerability of apremilast in children aged 6-17 years.
• While the trial is gearing up for recruitment, it's eyeing a finish line on December 17, 2026, aiming for an enrollment of 50 patients with plaque psoriasis.

Apremilast Through the Ages: Amgen's Continued Research

• The company has been putting Apremilast under the lens with nine other trials, aiming to evaluate its safety, efficacy, and tolerability for treating plaque psoriasis across pediatric to adult age groups. The drug, approved to treat plaque psoriasis and psoriatic arthritis in adults, has shown promising efficacy in pediatric trials for severe plaque psoriasis. Now, they are broadening its use to target young patients with mild to moderate manifestations of the disease.
• These studies, ranging from mid-stage to late-stage, have diverse enrollment figures, with numbers between 33 to 595 participants. The trials are set for completion from August 2009 to December 2026.

Beyond Apremilast: Amgen's Broad Therapeutic Portfolio

• Amgen is actively testing a roster of drugs: Rocatinlimab, Sotorasib, and Tarlatamab. They target a spectrum of conditions from Atopic Dermatitis, specific KRAS mutation-related tumors, Small Cell Lung Cancer to Neuroendocrine Prostate Cancer.
• The Rocatinlimab studies are in their late-stage, with an end goal set for March 2027. Sotorasib's research spans initial to late stages, with the curtain expected to fall by May 2027. Meanwhile, Tarlatamab's trials, which are in the initial and mid-stages, are set to conclude by November 14, 2024.

Competitive Landscape: The Race in Plaque Psoriasis Treatment

• The therapeutic domain of plaque psoriasis witnesses stiff competition with players like Arcutis Biotherapeutics, Akeso, and Innovent Biologics.
• Arcutis Biotherapeutics is also delving deep into PDE4 inhibitors, ARQ-154 foam and ARQ-151 cream, spanning mid to late stages, and is set for a January 2024 finish.
• Akeso's AK101, undergoing mid and late-stage trials, is eyeing an early 2023 end line.
• Innovent Biologics has its focus on IBI112, with studies projected to wrap up by June 2025. The presence of these competitors underscores the fervent efforts in the realm of plaque psoriasis treatment.

Sources: Clinicaltrials.gov, PubMed, Press Releases, and AppliedXL. This report is generated algorithmically and may not cover all ongoing industry-sponsored trials. AppliedXL implements rigorous AI vetting processes but cannot guarantee the completeness of all insights.